• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Anticorps Polyclonal de lapin anti-ORAOV1

ORAOV1 Polyclonal Antibody for IP, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

IP, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 32706-1-PBS

Synonymes

CIAB1, LTO1, Oral cancer-overexpressed protein 1, Protein LTO1 homolog, TAOS1

Galerie de données de validation

Filter:
  • Immunoprecipitation (IP) experiment of A431 cells using ORAOV1 Polyclonal antibody (32706-1-AP)

    IP experiment of A431 using 32706-1-AP (same clone as 32706-1-PBS)

    IP result of anti-ORAOV1 (IP:32706-1-AP, 4ug; Detection:32706-1-AP 1:500) with A431 cells lysate 1120 ug. This data was developed using the same antibody clone with 32706-1-PBS in a different storage buffer formulation.

Informations sur le produit

32706-1-PBS cible ORAOV1 dans les applications de IP, Indirect ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène ORAOV1 Protéine recombinante Ag38523
Nom complet oral cancer overexpressed 1
Masse moléculaire calculée15kDa，137aa
Poids moléculaire observé16 kDa
Numéro d’acquisition GenBankNM_153451.2
Symbole du gène ORAOV1
Identification du gène (NCBI) 220064
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

ORAOV1 (oral cancer overexpressed 1) is a candidate proto-oncogene that is frequently amplified and overexpressed in various human squamous cell carcinomas (SCCs), including oral, esophageal, and cervical cancers. In cervical cancer, silencing of ORAOV1 significantly inhibits the growth of HeLa cells by causing S-phase cell cycle arrest and activating apoptosis. Additionally, ORAOV1 is overexpressed in a variety of solid tumors and may promote tumor development by preventing ribosomal damage induced by reactive oxygen species (ROS). Therefore, ORAOV1 is not only an important tumor biomarker but also a potential therapeutic target for multiple cancers.

{{ptg:RelatedPrimaryAntibodies}}